Andere Sprachen Neumora Therapeutics, Inc.

Aktien

A3EVX4

US6409791000

NMRA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 31.05.2024			% 5 Tage	% 1. Jan.
9,9 ^USD	+2,17 %		+7,96 %	-41,94 %

14.05.	Transcript : Neumora Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:00 AM
14.05.	Neumora Therapeutics, Inc. kündigt Beginn einer Phase-2-Studie mit Navacaprant bei bipolarer Depression an	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Transcript : Neumora Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:00 AM	14.05.
Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression	14.05.
Neumora Therapeutics Shares Fall as Q1 Loss Narrows	07.05.
Neumora Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07.05.
Upcoming Earnings Buoy Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday	15.04.
Neumora's early-stage schizophrenia drug study put on hold	15.04.
U.S. FDA places clinical hold on Neumora's schizophrenia drug study	15.04.
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study	15.04.
NEUMORA THERAPEUTICS, INC. : JPMorgan Chase reste à l'achat	18.03.
NEUMORA THERAPEUTICS, INC. : RBC Capital Markets optimiste sur le dossier	08.03.
Neumora Therapeutics Q4 Loss Narrows	07.03.
Neumora Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07.03.
Neumora Therapeutics, Inc. Reported Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	07.03.
Neumora Therapeutics Names Kaya Pai Panandiker as Chief Commercial Officer	22.01.
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer	22.01.
NEUMORA THERAPEUTICS, INC. : Deutsche Bank Securities de acheteur à neutre sur le titre	12.12.
Neumora Therapeutics, Inc. Appoints Jason Duncan as Chief Legal Officer	12.12.
Neumora Therapeutics Starts Phase 1 Trial of NMRA-266 as Potential Treatment of Schizophrenia, Neuropsychiatric Disorders	27.11.
Neumora Therapeutics, Inc. Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study	27.11.
Neumora Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	01.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Neumora Therapeutics, Inc.

Aktien

A3EVX4

US6409791000

NMRA

Andere Sprachen

Filter